Overview

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

Status:
Completed
Trial end date:
2019-05-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Joseph Tuscano
University of California, Davis
Collaborator:
Millennium Pharmaceuticals, Inc.
Treatments:
Bortezomib
Doxorubicin
Liposomal doxorubicin